Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors.
Guidon Amanda C, Burton Leeann B, Chwalisz Bart K, +34 more·Journal for immunotherapy of cancer
Expanding the US Food and Drug Administration-approved indications for immune checkpoint inhibitors in patients with cancer has resulted in therapeutic success and immune-related adverse events (irAEs). Neurologic irAEs (irAE-Ns) have an incidence of 1%-12% and a high fatality rate relative to other irAEs. Lack…